A, d. B., T, B., & L, L. (2024). Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: A case report and review of the literature. Frontiers in oncology, 13, 1210873. https://doi.org/10.3389/fonc.2023.1210873
Chicago Style (17th ed.) CitationA, de Bernardi, Bachelot T, and Larrouquère L. "Long-term Response to Sequential Anti-HER2 Therapies Including Trastuzumab-deruxtecan in a Patient with HER2-positive Metastatic Breast Cancer with Leptomeningeal Metastases: A Case Report and Review of the Literature." Frontiers in Oncology 13 (2024): 1210873. https://doi.org/10.3389/fonc.2023.1210873.
MLA (9th ed.) CitationA, de Bernardi, et al. "Long-term Response to Sequential Anti-HER2 Therapies Including Trastuzumab-deruxtecan in a Patient with HER2-positive Metastatic Breast Cancer with Leptomeningeal Metastases: A Case Report and Review of the Literature." Frontiers in Oncology, vol. 13, 2024, p. 1210873, https://doi.org/10.3389/fonc.2023.1210873.
